Degenerative disease biotech Annexon Biosciences (ANNX) has priced its IPO of 14.75M common shares at $17.00/share (above range of $14-16), for expected gross proceeds of ~$250.8M.
Underwriters’ over-allotment is an additional 2,212,500 shares.
Trading kicks off today. Closing date is July 28.
Previously: Annexon sets IPO terms (July 20)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.